Shots:
- Merck has reported topline P-III (CORALreef Lipids) trial data assessing enlicitide decanoate vs PBO for the treatment of adults with hypercholesterolemia receiving mod. to high-intensity statins or are intolerant to statins
- Trial met its 1EP with significant LDL-C reduction at Wk. 24 & achieved 2EPs, showing reduced non-HDL-C, apolipoprotein B, & lipoprotein(a) levels; data to be presented at future conference & shared with global health authorities
- Enlicitide is a macrocyclic peptide that targets PCSK9, thereby blocking its interaction with LDL receptors & is being evaluated in CORALreef program, incl. CORALreef Outcomes (n=~14,500), CORALreef HeFH, & CORALreef AddOn trials
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Reports P-III (VICTOR) Trial Data of Verquvo (Vericiguat) for Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
